Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.09.07
- Author:
Xin WANG
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Anaplastic lymphoma kinase (ALK);
Epidermal growth factor receptor (EGFR);
Lung neoplasms
- MeSH:
Anaplastic Lymphoma Kinase;
Carcinoma, Non-Small-Cell Lung;
diagnosis;
enzymology;
genetics;
ErbB Receptors;
genetics;
Humans;
Lung Neoplasms;
diagnosis;
enzymology;
genetics;
Mutation;
Prognosis;
Receptor Protein-Tyrosine Kinases;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(9):686-691
- CountryChina
- Language:Chinese
-
Abstract:
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.
.
